Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Sanofi pays Regeneron $1B upfront, up to $7B milestones for four early-stage immunology assets
Co-development, immunology, antibody, milestone payments, commercialization - Read more

Profluent, BioMarin partner to design novel AI-optimized enzyme therapies for BioMarin's pipeline
Research collaboration, rare disease, AI/ML, protein engineering, drug discovery - Read more

United Immunity, Roche partner to evaluate UI-102 with atezolizumab in advanced solid tumors
Manufacturing agreement, oncology, small molecule, antibody, immunotherapy - Read more

IBA, Telix partner to distribute ARTMS's QIS solid-target cyclotron technology for global theranostics expansion
Distribution agreement, radiopharmaceuticals, theranostics, oncology, manufacturing - Read more

Cell and Gene Live is a one-day, investor & CEO summit dedicated exclusively to Cell and Gene therapy - the science, the manufacturing, and the investment driving advanced medicines forward. All happening on November 15, 2026.

(Hosted by Onyx at The Shard in London as part of London Life Sciences Week)

Speakers confirmed include:

• Steve Bates, OBE (Chair of the UK's Department of Life Sciences)
• Dr. Erik Wiklund (CEO of Circio)
• Edwin Stone (CEO of Cellular Origins)
+ many more!

Get your tickets here - for TLDR Biotech readers, use code ANIS20 at check-out for 20% off.

Eli Lilly shares Ph3 cardiovascular outcomes data for Foundayo (orforglipron) in type 2 diabetes and obesity
Small molecule, metabolic, GLP-1 agonist, type 2 diabetes, cardiovascular outcomes, obesity - Read more

Taiho Oncology's (azacitidine/cedazuridine) combo meets primary endpoint in Ph3 for myelodysplastic syndromes and chronic myelomonocytic leukemia
Small molecule, cancer, oral combination therapy, myelodysplastic syndromes, acute myeloid leukemia, cytidine deaminase inhibitor - Read more

Roche's Vabysmo (faricimab) shows real-world effectiveness across neovascular age-related macular degeneration, diabetic macular edema, and retinal vein occlusion
Antibody, ophthalmology, monoclonal antibody, faricimab, age-related macular degeneration, diabetic macular edema - Read more

AbbVie's zumilokibart (zumilokibart) shows Ph2 success in moderate to severe atopic dermatitis across all doses
Antibody, autoimmune, monoclonal antibody, atopic dermatitis, IL-31 pathway, phase 2 - Read more

Varda raises $251M Series D to manufacture pharmaceuticals in space
Space-based manufacturing, pharmaceutical processing, drug formulation, platform technology - Read more

Immix Biopharma raises $125M underwritten offering, advancing relapsed/refractory AL Amyloidosis treatments
AL amyloidosis, cell therapy, clinical-stage, rare disease - Read more

R1 Therapeutics extends Series A to $80.5M, advancing kidney disease therapy AP306
Kidney disease, small molecule, clinical-stage, cardiovascular - Read more

Ray Therapeutics receives $8M CIRM grant to advance RTx-021 Stargardt disease trial
Gene therapy, optogenetics, rare disease, retinal disease, clinical-stage - Read more

Astrocyte Pharmaceuticals raises $9.5M Series B, advancing Phase 2 cerebroprotective therapy for brain injury
Neurological, clinical-stage, cerebroprotective, traumatic brain injury, small molecule - Read more

AnaCardio raises €62.5M ($70.9M) Series B, advancing AC01 for chronic heart failure treatment
Cardiovascular, heart failure, small molecule, clinical-stage - Read more

Roche Diagnostics launches single-assay newborn screening test simultaneously detecting SMA, SCID, and SCD
In vitro diagnostic, rare disease, operational, competitive - Read more

HHS launches SURPASS programme via ARPA-H to accelerate, cut costs of clinical trials
Clinical trial technology, multiple disease areas, regulatory, operational - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Boehringer Ingelheim, Zealand Pharma's (survodutide) Ph3 trial meets endpoints in obesity with Type 2 diabetes, but efficacy underwhelms analysts
Small molecule, metabolic, GLP-1 receptor agonist, obesity, type 2 diabetes, dual agonist - Read more

BMS reports liver injury events in Ph3 (admilparant) program for idiopathic pulmonary fibrosis ahead of key readout
Small molecule, pulmonary disease, LPA1 antagonist, idiopathic pulmonary fibrosis, liver toxicity, safety signal - Read more

Novo cuts 108 jobs at US New Jersey headquarters amid broader global restructuring efforts
Restructuring, diabetes, cost reduction, operational - Read more

BioMarin lays off 117 California workers to consolidate its Novato manufacturing footprint
Enzyme replacement therapy, rare disease, cost reduction, operational - Read more

Foghorn Therapeutics cuts 40% of staff after Eli Lilly oncology collaboration ends over failed trial
Small molecule, oncology, cost reduction, strategic - Read more

CMS finalizes GLOBE Model, applying most-favored nation pricing to Medicare Part B starting 2026
Medicare Part B, drug pricing, cost reduction, regulatory - Read more

FDA issues warning letter to Fresenius Kabi over manufacturing failures linked to patient adverse events
Small molecule, gastrointestinal, operational, manufacturing compliance - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here